# Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

> **NCT00321646** · PHASE2 · COMPLETED · sponsor: **Mary-Ellen Taplin, MD** · enrollment: 42 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00321646
- **Lead sponsor:** Mary-Ellen Taplin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-11
- **Final completion:** 2012-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321646, "Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00321646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*